DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20213928

Correlation between cholesterol levels and the severity of Parkinson disease

Sandy Kumala, Rizal Tumewah, Sekplin A. S. Sekeon

Abstract


Background: Parkinson disease is the second most common neurodegenerative disease after dementia Alzheimer. In neurodegenerative disease such as PD, there is a disturbance of cholesterol metabolism in the brain that could affect plasma cholesterol level. Laboratory test of cholesterol level could be used as an alternative parameter in assessing the severity degree of PD. Our objectives in this study are to analyze the correlation between cholesterol level and the severity of PD. 

Methods: This study is a cross sectional study. The sample is collected from patients with PD that came too neurology clinic in Prof Dr. R. D. Kandou Manado Hospital. Patients will then be assessed whether they meet the inclusion criteria which is examined using unified Parkinson disease rating scale (UPDRS) questionnaire and Hoehn and Yahr (H and Y). If the inclusion criteria are met, subject will be tested for total cholesterol, high density lipoprotein (HDL), and low density lipoprotein (LDL) levels in plasma.

Results: There are 60 subjects of PD patients with mean age 64.37±8.26 years old. Male subjects were more dominant (53.3%) than female. Total cholesterol level and LDL have moderate negative correlation with UPDRS I, UPDRS II, UPDRS III, and UPDRS total score. Total cholesterol and LDL level also has moderate negative correlation with H and Y severity.

Conclusions: There is a moderate negative correlation between total cholesterol level and LDL with PD severity degree based on H&Y degree and UPDRS I, II, III, and UPDRS total score. 


Keywords


Cholesterol level, UPDRS, H and Y, Parkinson disease

Full Text:

PDF

References


Basjiruddin A. Gejala non motorik penyakit parkinson. in: buku panduan tatalaksana penyakit parkinson dan gangguan gerak lainnya. kedua. Kelompok Studi Movement Disorder Perdossi. 2015; 5:33-62.

Dorsey ER, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC, et al. Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-53.

Tan LC. Epidemiology of Parkinson’s disease. Neurol Asia. 2013;8.

Thamrin S. Buku Panduan Tatalaksana Penyakit Parkinson dan Gangguan Gerak Lainnya. Kedua. Kelompok Studi Movement Disorder Perdossi. 2015; 7:9-31.

Skorvanek M, Martinez-Martin P, Kovacs N, Rodriguez-Violante M, Corvol J-C, Taba P, et al. Differences in MDS-UPDRS Scores based on hoehn and yahr stage and disease duration. Mov Disord Clin Pract. 2017;4(4):536-44.

Egawa J, Pearn ML, Lemkuil BP, Patel PM, Head BP. Membrane lipid rafts and neurobiology: age-related changes in membrane lipids and loss of neuronal function: Membrane lipid rafts, Cav-1 and neuroplasticity. J Physiol. 2016;594(16):4565-79.

Kathleen MB, Peter AM. Cholesterol synthesis, transport, & excretion. In: Harper’s Illustrated Biochemistry. 31st ed. New York: McGraw-Hill; 2018:617-42.

Jin U, Park SJ, Park SM. Cholesterol Metabolism in the brain and its association with Parkinson’s disease. Exp Neurobiol. 2019;28(5):554-67.

Zhang J, Liu Q. Cholesterol metabolism and homeostasis in the brain. Protein Cell. 2015;6(4):254-64.

Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. Cardiovasc Res. 2014;103(3):405-13.

Agustin NN, Gofir A. Pengaruh kadar low density lipoprotein cholesterol (LDL-C) terhadap derajat keparahan penyakit Parkinson. J Univ Gajah Mada. 2017;6:52-9.

Sari H, Harris S, Hakim M, Misbach Y. Perubahan fungsional penyakit parkinson dengan menggunakan unified Parkinson’s disease rating scale (UPDRS). Exp Neurobiol. 2010; 2010:27.

Huang X, Chen H, Miller WC, Mailman RB, Woodard JL, Chen PC, et al. Lower low density lipid cholesterol levels are associated with Parkinson’s disease. J Physiol. 2007;7:115-9.

Oktariza Y, Amalia L, Sobaryati S, Kurniawati MY. Evaluasi Kualitas Hidup Pasien Parkinson Berdasarkan Terapi Berbasis Levodopa. Indones J Clin Pharm. 2019;8(4):246.

Larasanti P, Samatra PDPG, Sumada K, Trisnawati Y. Karateristik Klinis dan derajat berat gejala motorik penyakit parkinson di rsup sanglah dan rsud wangaya denpasar. Callosum Neurol. 2020;3:6-11.

Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson’s disease. Parkinsonism Relat Disord. 2010;16(2):79-84.

Pariama G, Kustilowati E. Hubungan Disabilitas berdasarkan unified parkinson disease rating scale dengan disfungsi ereksi pada penyakit parkinson. Neurona. 2016;33:279-84.

Miyake Y, Sasaki S, Tanaka K, Fukushima W, Kiyohara C, Tsuboi Y, et al. Dietary fat intake and risk of Parkinson’s disease: A case-control study in Japan. J Neurol Sci. 2010;288(1-2):117-22.

Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, et al. Serum Cholesterol and the Progression of Parkinson’s Disease: Results from DATATOP. PLoS ONE. 2011; 6(8):e22854.

Nakamura K, Mori F, Tanji K, Miki Y, Yamada M, Kakita A, et al. Isopentenyl diphosphate isomerase, a cholesterol synthesizing enzyme, is localized in Lewy bodies: IDI1 and IDI2 in Lewy bodies. Neuro pathology. 2015;35(5):432-40.